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O-GlcNAcylation is a key post-translational modification that modifies the
functions of proteins. Associations between O-GlcNAcylation, shorter sur-
vival of cholangiocarcinoma (CCA) patients, and increased migration/inva-
sion of CCA cell lines have been reported. However, the specific
O-GlcNAcylated proteins (OGPs) that participate in promotion of CCA
progression are poorly understood. OGPs were isolated from human CCA
cell lines, KKU-213 and KKU-214, using a click chemistry-based enzy-
matic labeling system, identified using LC-MS/MS, and searched against
an OGP database. From the proteomic analysis, a total of 21 OGPs related
to cancer progression were identified, of which 12 have not been previously
reported. Among these, hnRNP-K, a multifaceted RNA- and DNA-bind-
ing protein known as a pre-mRNA-binding protein, was one of the most
abundantly expressed, suggesting its involvement in CCA progression.
O-GlcNAcylation of hnRNP-K was further verified by anti-OGP/anti-
hnRNP-K immunoprecipitations and sWGA pull-down assays. The perpet-
uation of CCA by hnRNP-K was evaluated using siRNA, which revealed
modulation of cyclin D1, XIAP, EMT markers, and MMP2 and MMP7
expression. In native CCA cells, hnRNP-K was primarily localized in the
nucleus; however, when O-GlcNAcylation was suppressed, hnRNP-K was
retained in the cytoplasm. These data signify an association between
nuclear accumulation of hnRNP-K and the migratory capabilities of CCA
cells. In human CCA tissues, expression of nuclear hnRNP-K was posi-
tively correlated with high O-GlcNAcylation levels, metastatic stage, and
shorter survival of CCA patients. This study demonstrates the significance
of O-GlcNAcylation on the nuclear translocation of hnRNP-K and its
impact on the progression of CCA.
Abbreviations
CCA, cholangiocarcinoma; EMT, epithelial to mesenchymal transition; GlcNAc, N-acetylglucosamine; hnRNP-K, heterogeneous nuclear
ribonucleoprotein-K; IHC, immunohistochemistry; MMP, matrix metalloproteinase; OGA, O-GlcNAcase; OGPs, O-GlcNAcylated proteins;
OGT, O-GlcNAc transferase; sWGA, succinylated wheat germ agglutinin.
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1. Introduction
O-GlcNAcylation is a post-translational modification
of proteins in which a single sugar, N-acetylglucosa-
mine (GlcNAc), is covalently attached to the hydroxyl
group of a serine or threonine residue on a polypep-
tide. The bioassembly is a dynamic process catalyzed
by two enzymes, O-GlcNAc transferase (OGT) and O-
GlcNAcase (OGA), which adds and removes the
GlcNAc to and from the protein, respectively (Hart
et al., 2007). Protein properties and functions are
known to be modulated via O-GlcNAcylation, for
example, phosphorylation, interactions, degradation,
and localization. Several evidences have indicated the
association of aberrant O-GlcNAcylation with many
human diseases including cancer (Hart et al., 2011;
Singh et al., 2015; Zachara and Hart, 2006). The sig-
nificance of O-GlcNAcylation in cancer metastasis has
been demonstrated in vitro and in vivo. Suppression of
OGT using shRNA resulted in inhibition of metastasis
in xenografted mouse models of breast cancer (Ferrer
et al., 2017; Gu et al., 2010), cervical cancer (Ali et al.,
2017), and prostate cancer (Lynch et al., 2012).
We have previously reported the correlation of high
O-GlcNAcylation levels with shorter survival of
cholangiocarcinoma (CCA) patients (Phoomak et al.,
2012). Specifically, increased O-GlcNAcylation of
vimentin, a major intermediate filament protein, per-
suaded its stability and is implicated in the aggression
of CCA cells. In addition, promotion of CCA aggres-
siveness under high glucose conditions was shown to
be via elevation of OGT and O-GlcNAcylation (Phoo-
mak et al., 2017). On the other hand, suppression of
OGT with siRNA significantly reduced cell migration
and invasion of CCA cells (Phoomak et al., 2016).
According to the O-GlcNAcylated proteins database
(dbOGAP) (Wang et al., 2011), there are only about
800 O-GlcNAcylated proteins reported at present. In
this context, there may be a number of O-GlcNAcy-
lated proteins (OGPs) associated with progression of
cancer that remain unidentified. Historically, progress
has been hampered in part by the technical difficulties
in detection of OGPs (Hart et al., 2007). However,
with the recent development of more sophisticated
mass spectrometric methods in combination with bio-
chemical tools, including enhancement of OGPs using
OGA inhibitors, identification of OGPs has been
markedly improved (Hart et al., 2007).
This study was aimed to determine novel OGPs that
modulate progression of CCA cells. OGPs were first
globally enriched and labeled using Click-iTTM O-
GlcNAc Enzymatic Labeling System, and then
identified using Q Exactive Plus Orbitrap mass spec-
trometry. Heterogeneous nuclear ribonucleoprotein-K
(hnRNP-K) was selected and validated for its
O-GlcNAcylation status and involvement in CCA pro-
gression. The signal pathways related to hnRNP-K in
association with migration and invasion activities of
CCA cells were subsequently determined. Specifically,
O-GlcNAcylation of hnRNP-K was implicated in
mediation of nuclear translocation in addition to
migration of CCA cells. Moreover, association of
O-GlcNAcylation levels and hnRNP-K expression was
observed in tumor tissues of CCA patients in associa-
tion with metastatic stage and shorter survival of
patients. Significantly, these results implicate hnRNP-
K O-GlcNAcylation as a promising therapeutic target
to suppress CCA progression.
2. Materials and methods
2.1. Antibodies and reagents
Antibodies were purchased from various sources: anti-
O-GlcNAc (RL-2, MA1-072) from Pierce Biotechnol-
ogy (Rockford, IL, USA); anti-hnRNP-K (H-300,
sc-25373), anticyclin D1 (H-295, sc-753), anti-XIAP
(H-202, sc-11426), anti-MMP2 (H-76, sc-10736), anti-
MMP7 (JL07, sc-80205), and anti-OGT (F-12, sc-
74546) from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); anticleaved caspase 3 (D175, 5A1E,
#9664), anti-E-cadherin (24E10, #3195), anticlaudin-1
(D5H1D, #13255), antivimentin (D21H3, #5741), and
antislug (C19G7, #9585) from Cell Signaling (Danvers,
MA, USA); PUGNAc (O-(2-acetamido-2-deoxy-d-glu-
copyranosylidene) amino-N-phenylcarbamate) from
Sigma-Aldrich (St. Louis, MO, USA).
2.2. CCA cell culture and CCA tissues
CCA cell lines (KKU-100, KKU-213, and KKU-214)
were obtained from the Japanese Collection of
Research Bioresources (JCBR) Cell Bank (Osaka,
Japan). MMNK1, an immortal cholangiocyte cell line,
was a gift from Kobayashi N. (Maruyama et al.,
2004). Cells were cultured in DMEM—Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Grand
Island, NY, USA) supplemented with 10% FBS and
1% antibiotic–antimycotic under standard protocol.
Transient enhancement of O-GlcNAcylation was per-
formed by culturing cells in the presence of 20 lM
PUGNAc for 24 h prior to further experiments.
The immunohistochemistry (IHC) experiments were
performed using formalin-fixed paraffin-embed liver
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tissues from histologically proven CCA patients. Each
subject gave informed consent, and the study protocol
was certified by the Ethics Committee for Human
Research at Khon Kaen University (HE581369).
2.3. Identification of O-GlcNAcylated proteins
The Click-iTTM O-GlcNAc Enzymatic Labeling Sys-
tem (Invitrogen, Carlsbad, CA, USA) was used to
detect the OGPs in CCA cells. As shown in Fig. S1,
cells were homogenized and N-linked glycans were
released as described previously (Park et al., 2016).
Protein (2 mg) was trypsinized with 1 lg trypsin at
37°C overnight. The peptides were enriched with
C-18 column (Discovery DSC-18, 52603U, Sigma)
as standard protocol for solid-phase extraction (Yang
et al., 2016). O-GlcNAcylated peptides were enzymat-
ically labeled with azido-modified galactose (GalNAz)
by mutant b-1,4-galactosyltransferase (Gal-T1
(Y289L)). The labeled peptides were tagged with bio-
tin-alkyne by Click-iTTM Biotin Protein Analysis
Detection Kit (Invitrogen). The complex was then
pulled down with streptavidin–agarose resin (Thermo
Scientific, Waltham, MA, USA) at 4 °C overnight.
The peptides were cleaved by mild b-elimination and
Michael addition (BEMAD; 1.5% triethylamine,
20 mM dithiothreitol, pH 12-12.5 with NaOH). The
reaction was incubated at 54 °C for 4 h with shaking
and stopped by addition of 2% trifluoroacetic acid.
The peptides were enriched and analyzed using a Q
Exactive Plus Orbitrap mass spectrometer (Thermo
Scientific; Park et al., 2015). A 60-min binary gradi-
ent was applied using 0.1% (v/v) formic acid in (A)
water and (B) acetonitrile. The parameters of protein
identification were set as follows: spray voltage
2.2 kV; ion transfer capillary temperature 200 °C; MS
automatic gain control 1 9 106; MS maximum injec-
tion time 30 ms; MS/MS automatic gain control
5 9 104; MS/MS maximum injection time 50 ms; iso-
lation width 1.6; normalized collision energy 27;
charge state preference 2–8. The proteomics data were
analyzed by X!Tandem (Craig and Beavis, 2004).
Identified proteins were matched to the human pro-
teome (SWISSPROT) and the Database of O-GlcNA-
cylated Proteins and Sites (dbOGAP) (Wang et al.,
2011).
2.4. Transient suppression of hnRNP-K
expression using specific siRNA
hnRNP-K expression in CCA cells was suppressed
using siRNA (Zhang et al., 2016b) as previously
reported (Phoomak et al., 2016). Cells treated with
scramble siRNA (Negative Control siRNA, 1027310,
Qiagen, Hilden, Germany) were used as the control.
2.5. Cell proliferation
Viable cells were measured using the WST-8 proliferation
assay (Cell Counting Kit-8 (CCK-8), Dojindo Molecular
Technologies, Inc., Rockville, MD, USA) according to
the manufacturer’s guidelines. The absorbance of soluble
WST-8 formazan was measured at 450 nm. Cell numbers
were calculated as % of control cells.
2.6. Cell migration and invasion
CCA cells (40 000 cells) were placed into the upper
chamber of a 8.0 lm pore size transwell-cell culture
inserts (Corning Incorporated, Corning, NY, USA) for
migration and invasion assays as previously described
(Phoomak et al., 2016). Cells were allowed to migrate
or invade: 9 h for KKU-213 and 24 h for KKU-214.
The migrated and invaded cells underneath the filter
were stained and counted under a microscope with
109 objective lens. Experiments were performed in
triplicate, and cells from 5 microscopic fields/insert
were determined and calculated as % of control.
2.7. Immunoprecipitation
Cell lysate was prepared and immunoprecipitation was
performed as previously described (Phoomak et al.,
2016). Briefly, cell lysates (500 lg) were immunopre-
cipitated with 2 lg anti-O-GlcNAc or anti-hnRNP-K
at 4 °C, overnight. The immunoprecipitated complex
was separated and solubilized in SDS sample buffer
prior to SDS/PAGE and western blotting.
2.8. Succinylated wheat germ agglutinin (sWGA)
pull-down assay
The sWGA pull-down assay was performed as previ-
ously described (Kang et al., 2009). In brief, 500 lg of
cell lysates was incubated with 40 lL of agarose-conju-
gated sWGA (Vector Laboratories, Burlingame, CA,
USA) with or without 0.25 M GlcNAc at 4 °C, over-
night. The precipitates were washed four times with
NET lysis buffer and boiled in SDS sample buffer.
2.9. SDS/PAGE and western blot analysis
Cells were lysed in lysis buffer (1% NP-40, 150 mM
NaCl, 50 mM Tris/HCl pH 7.4) containing 5 lM PUG-
NAc, phosphatase, and protease inhibitors. The SDS/
PAGE and western blot were performed as previously
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described (Phoomak et al., 2016). The ECLTM Prime
Western Blotting Detection System and the images
were analyzed using an ImageQuant LAS 4000 mini
image analyzer and ImageQuantTM TL analysis soft-
ware (GE Healthcare, Buckinghamshire, UK).
2.10. Immunocytofluorescence
Cells were prepared for immunocytofluorescence as
previously described (Phoomak et al., 2016). After fix-
ation, cells were then incubated with 1:100
anti-hnRNP-K overnight at 4 °C and with 1:200 anti-
rabbit-IgG-PE (Santa Cruz) for 1 h at room tempera-
ture. To visualize nuclei, cells were stained with
1:10 000 Hoechst 33342 (Molecular Probes, Invitrogen,
Paisley, UK). The fluorescence image was taken using
a ZEISS LSM 800 Confocal Laser Scanning Micro-
scope (Zeiss, Oberkochen, Germany).
2.11. Immunohistochemistry
Expression of hnRNP-K and OGP in CCA tissues was
determined using immunohistochemistry (IHC) stain-
ing according to the standard protocol. The signals
were amplified using the EnVision-system-HRP (Dako,
Glostrup, Denmark). The immunoreactivity signals
were developed using diaminobenzidine (Sigma-
Aldrich). The IHC score was determined as described
previously (Phoomak et al., 2017). Two independent
assessors scored the levels of IHC staining signal
blindly without prior knowledge of clinical parameters.
2.12. Statistical analysis
All statistics were analyzed using the GraphPad
Prism 5.0 software (GraphPad software, Inc., La
Jolla, CA, USA). Student’s t-test was used to compare
parameters between two samples. The correlation
between OGP level and hnRNP-K expression in CCA
patient tissues was determined using Fisher’s exact
test, Mann–Whitney test, and Spearman’s rank corre-
lation test. Differences were considered statistically sig-
nificant if P < 0.05.
3. Results
3.1. Increasing O-GlcNAcylation enhances
migration and invasion abilities of CCA cells
As PUGNAc, an inhibitor of OGA was used to enrich
the O-GlcNAcylation in CCA cells, we first determined
whether PUGNAc treatment could increase O-GlcNA-
cylation and enhance progression of CCA cells. CCA
cells (KKU-213 and KKU-214) were treated with
PUGNAc for 24 h, and the OGP level together with
migration and invasion abilities of CCA cells treated
with or without PUGNAc was determined. As shown
in Fig. 1A, suppression of OGA activity using PUG-
NAc increased the levels of OGP in CCA cells 2.5-fold
in KKU-213 and 3.0-fold in KKU-214, respectively.
PUGNAc treatment also significantly enhanced the
relative migratory ability to 165% in KKU-213 and to
175% in KKU-214 compared with the control cells
(Fig. 1B). Similar results were also observed for the
invasion ability. PUGNAc treatment increased inva-
sion of KKU-213 to 175% and of KKU-214 to 150%
compared with those of control cells (Fig. 1C).
3.2. Novel O-GlcNAcylated proteins related to
progression of CCA cells were revealed by
enzymatic labeling and mass spectrometry
analysis
To increase the sensitivity of OGP detection, O-
GlcNAcylated peptides were labeled with GalNAz by
GalT1 (Y289L) and tagged with biotin-alkyne. The
labeled peptides were then analyzed by mass spectrom-
etry (Fig. S1). Over 100 OGPs were identified in cell
lysates from KKU-213 and KKU-214 (Tables S1), of
which the major OGPs were found in the cytoplasm
and nucleus (Fig. S2A).
To classify the OGPs that are related to progression
of CCA cells, the primary list of OGPs obtained from
mass spectrometry were filtered according to the fol-
lowing parameters: (1) it was present in both KKU-
213 and KKU-214 cells, and (2) it had at least one
predicted O-GlcNAcylation site (based on dbOGAP).
There were 21 OGPs that passed these criteria. The
description, cellular localization, and functions of these
OGPs are listed according to the intensity of the pep-
tides in Table 1. Twelve OGPs listed may be novel
OGPs as their O-GlcNAcylation has not been identi-
fied (Fig. S2B). The involvement of these OGPs in bio-
logical processes is summarized in Fig. S2C.
3.3. Immunoprecipitation reveals O-GlcNAc
modification of hnRNP-K
hnRNP-K, a multifaceted RNA- and DNA-binding
protein associated with pre-mRNA, mRNA metabo-
lism and transport (Dejgaard and Leffers, 1996; Lu
and Gao, 2016), has been shown to contribute to
metastasis in several cancer types (Chung et al., 2014;
Gao et al., 2013; Zhang et al., 2016b; Zhou et al.,
2010). Moreover, hnRNP-K possesses multiple Ser/
Thr sites that are predicted to be O-GlcNAcylated.
341Molecular Oncology 13 (2019) 338–357 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
C. Phoomak et al. O-GlcNAcylation of hnRNP-K induces CCA metastasis
Fig. 1. O-GlcNAcylation promotes CCA migration and invasion. CCA cells, KKU-213 and KKU-214, were treated with 20 lM PUGNAc for
24 h. (A) OGP levels were determined using western blot. (B) Migration and (C) invasion abilities of PUGNAc-treated CCA cells were
compared with those of the vehicle control cells. The results represent one of two independent experiments (mean  SEM, *P < 0.05;
**P < 0.01, Students’ t-test). The images shown are 100 9 magnification with 50 lm of scale bar.
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Therefore, hnRNP-K was selected for verification of
its O-GlcNAc modification and involvement in CCA
progression.
To prove the modification of O-GlcNAc on hnRNP-
K, an immunoprecipitation assay was performed. Cell
lysates of CCA cells treated with PUGNAc or vehicle
were subjected to immunoprecipitation using anti-OGP.
Immunoprecipitation using mouse immunoglobulin
(IgG) as an isotype control was used to clarify the speci-
ficity of the anti-OGP. As shown in Fig. 2A, PUGNAc
Table 1. List of O-GlcNAcylated proteins related with proliferation and progression of cancer.
UniProt
accession Gene name Protein description log(intensity)a
Cellular
compartmentb Function Reference
Reported O-GlcNAcylated proteins
P60709 ACTB Actin, beta 8.33 Cytoplasm – –
P16403 HIST1H1C Histone cluster 1 H1c 7.78 Nucleus Proliferation Song et al. (2008)
Migration
Invasion
P10412 HIST1H1E Histone cluster 1 H1e 7.74 Nucleus Proliferation Lee et al. (2013)
P16401 HIST1H1B Histone cluster 1 H1b 7.69 Nucleus Carcinogenesis Khachaturov et al. (2014)
P02545 LMNA Lamin A/C 7.56 Nucleus Proliferation Kong et al. (2012)
Migration
Invasion
P06748 NPM1 Nucleophosmin
(nucleolar phosphoprotein
B23 numatrin)
7.49 Cytoplasm Proliferation Ching et al. (2015)
Nucleus Migration
Invasion
P22626 NRNPA2B1 Heterogeneous
nuclear ribonucleoprotein
A2/B1
7.32 Nucleus Proliferation Chen et al. (2014)
Migration
Invasion
Q09666 AHNAK AHNAK nucleoprotein 7.10 Nucleus Proliferation Sudo et al. (2014)
Migration
Invasion
P07355 ANXA2 Annexin A2 7.07 Membrane Proliferation Chaudhary et al. (2014)
and Wang et al. (2015)Cytoplasm Migration
Nucleus Invasion
Unreported O-GlcNAcylated proteins
P46939 UTRN Utrophin 8.49 Membrane Proliferation Li et al. (2007)
Cytoplasm
Q5QNW6 HIST2H2BF Histone cluster 2 H2bf 8.43 Nucleus – –
P62805 HIST1H4A Histone cluster 2 H4a 8.16 Nucleus Proliferation Yan-Fang et al. (2015)
B9ZVM9 TCP10L2 T-complex protein
10A homolog 2
7.95 Nucleus Proliferation (Shen et al., 2015)
Q16695 HIST3H3 Histone cluster 3 H3 7.50 Nucleus Proliferation (Xu et al., 2014)
P08195 SLC3A2 Solute carrier family 3
(amino acid transporter
heavy chain), member 2
7.09 Membrane Proliferation Fei et al. (2014),
Santiago-Gomez et al. (2013)
and Yang et al. (2007)
Cytoplasm Migration
Nucleus Invasion
Q16819 MEP1A Meprin A subunit alpha 6.96 Membrane Migration Minder et al. (2012)
Invasion
P61978 HNRNPK Heterogeneous nuclear
ribonucleoprotein-K
6.81 Cytoplasm Proliferation Chung et al. (2014) and
Gao et al. (2013)Nucleus Migration
Invasion
P27824 CANX Calnexin 6.73 Cytoplasm Carcinogenesis Dissemond et al. (2004)
Metastasis
Q08170 SRSF4 Serine/arginine-rich
splicing factor 4
6.26 Nucleus Proliferation Gabriel et al. (2015)
Q5T200 ZC3H13 Zinc finger CCCH-type
containing 13
– –
Q7Z7G8 VPS13B Vacuolar protein sorting
13 homolog B
– –
aLog (intensity) of identified OGPs in KKU-213.
bAccording to GeneCards: The Human Gene Database.
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treatment increased the expression level of OGPs and
signal of hnRNP-K in the immunoprecipitated-OGP
from both KKU-213 and KKU-214 cells. Similar results
were obtained for the reversed-immunoprecipitation
using anti-hnRNP-K (Fig. 2B). In both cell lines, the
signal of OGP was higher in the immunoprecipitate of
hnRNP-K from PUGNAc-treated cells than that from
the control cells. These data demonstrated the O-
GlcNAc modification of hnRNP-K. As succinylated
wheat germ agglutinin (sWGA) specifically recognizes
the sugar moiety of GlcNAc, an sWGA pull-down assay
was performed to further ensure that hnRNP-K was O-
GlcNAcylated. As shown in Fig. 2C, the signal of
hnRNP-K in the sWGA pull-down precipitate from
PUGNAc-treated cells was higher than that of the con-
trol cells. The specific interaction between O-GlcNAcy-
lated hnRNP-K and sWGA was assured by the
neutralization of sWGA with GlcNAc. The signals of
O-GlcNAcylated hnRNP-K, sWGA-conjugated pro-
teins, and O-GlcNAcylated proteins were diminished in
the GlcNAc-neutralized sWGA condition. In addition,
the level of O-GlcNAcylation of hnRNP-K was elevated
when cellular O-GlcNAcylation was increased. Collec-
tively, these results indicate the O-GlcNAcylation of
hnRNP-K.
3.4. hnRNP-K is required for cell proliferation,
migration, and invasion of CCA cells
We next investigated the involvement of hnRNP-K in
CCA progression, indicated namely by increases in cell
proliferation, migration, and invasion. To this end, the
expression of hnRNP-K was transiently suppressed by
siRNA, and cell proliferation, migration, and invasion
were determined in comparison with those of the
scramble control cells. The si-hnRNP-K transfection
could reduce the expression of hnRNP-K to 30% of
the control cells in KKU-213 and to 25% in KKU-
214 (Fig. 3A). Proliferation rates of KKU-213 and
KKU-214 were significantly decreased when the
expression of hnRNP-K was suppressed for 48 h
(Fig. 3B). Moreover, diminution of hnRNP-K expres-
sion markedly decreased the motility of CCA cells to
36% of the control cells in KKU-213 and to 27% in
KKU-214 (Fig. 3C). Similar effects were also observed
for the invasion ability of CCA cells. The invasion
ability of si-hnRNP-K-treated cells was 50% and 15%
of the control cells in KKU-213 and KKU-214,
respectively (Fig. 3D). These data indicated the associ-
ation of hnRNP-K with the proliferation, migration
and invasion of CCA cells. To ensure that the
observed effects of hnRNP-K on migration and inva-
sion were not due to changes in growth rates, we
parallelly measured cell proliferation. As shown in
Fig. S3, there were no growth differences between si-
hnRNP-K- and scramble siRNA-treated cells during
the time of assays. Thus, si-hnRNP-K conferred
decreases in migration and invasion without affecting
cell growth.
3.5. Key markers related to growth and
metastasis proteins are influenced by hnRNP-K
Given that hnRNP-K is a multifaceted RNA- and
DNA-binding protein, we further examined the influ-
ence of hnRNP-K on key effector proteins related to
these malignant phenotypes: cyclin D1 for cell prolifer-
ation, XIAP for antiapoptosis, cleaved caspase 3 for
cell apoptosis, E-cadherin and claudin-1 for epithelial
markers, vimentin and slug for mesenchymal markers,
and MMP2 and MMP7 for invasion activity. Specifi-
cally, the expression of cyclin D1 and XIAP was inves-
tigated after hnRNP-K was suppressed by siRNA for
24, 48, and 72 h. Compared to the control cells, the
expression of cyclin D1 and XIAP in si-hnRNP-K-
treated KKU-213 and si-hnRNP-K-treated-KKU-214
cells decreased along with hnRNP-K expression until
72 h (Fig. 4A). In addition, the level of cleaved cas-
pase 3 increased with time in si-hnRNP-K-treated
cells. The quantitative data are shown in Fig. 4B.
To determine the effect of hnRNP-K on the effector
proteins related to cell migration and invasion, the
expression of epithelial to mesenchymal transition
(EMT) markers (e.g., E-cadherin, claudin-1, vimentin,
and slug), and matrix metalloproteinase (MMP) 2 and
MMP7 was determined in si-hnRNP-K-treated cells in
comparison with those of the scramble control cells.
As shown in Fig. 4C,D, the expression levels of E-cad-
herin and claudin-1 increased whereas those of vimen-
tin and slug decreased in si-hnRNP-K-treated cells. On
the other hand, while si-hnRNP-K treatment sup-
pressed the MMP2 expression after 24 h of treatment,
expression of MMP7 gradually decreased with time.
These data demonstrated that hnRNP-K influenced
cell migration and invasion in association with the
expression of EMT, MMP2, and MMP7.
To emphasize the connection of O-GlcNAcylation
levels, hnRNP-K and its downstream signals, the
expression level of O-GlcNAcylation, hnRNP-K,
cyclin D1, XIAP, and EMT markers was determined
in CCA cell lines, KKU-100, which shows lower
migration activity versus KKU-213. As shown in
Fig. 4E, compared to KKU-213, KKU-100 exhibited
not only lower levels of O-GlcNAcylation but also
lower levels of hnRNP-K and the effector molecules
related to migration and invasion.
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Fig. 2. Validation of hnRNP-K O-GlcNAcylation. CCA cells (KKU-213 and KKU-214) were treated with PUGNAc or vehicle for 24 h. The cell
lysates were immunoprecipitated with either (A) anti-OGP or (B) anti-hnRNP-K and probed with anti-hnRNP-K and anti-OGP. Human
immunoglobulin G (IgG) isotype was used as the controls of the specificity of the antibodies that were used in the immunoprecipitation
assay. (C) The sWGA pull-down assay was performed using sWGA-conjugated agarose and probed with anti-hnRNP-K, sWGA, and anti-
OGP. GlcNAc neutralization was used to examine the specific binding of sWGA to the OGPs.
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Fig. 3. Suppression of hnRNP-K reduces proliferation, migration, and invasion of CCA cells. The expression of hnRNP-K was transiently
suppressed by siRNA for 48 h prior to the migration and invasion assays. (A) The expression of hnRNP-K was determined using western
blot. (B) Cell proliferation, (C) migration, and (D) invasion abilities of si-hnRNP-K-treated CCA cells were compared with those of the
scramble siRNA (sc)-treated cells. The migration and invasion assays were conducted for 9 h in KKU-213 and 24 h in KKU-214. The images
shown are 100 9 magnification with 50 lm scale bar. Data are mean  SEM (*P < 0.05; **P < 0.01; ***P < 0.001, Students’ t-test).
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To investigate whether enhancing O-GlcNAcylation
of hnRNP-K could support the migratory activity of
cells, two additional cell lines with low hnRNP-K
expression were enrolled, MMNK1, an immortal
cholangiocyte, and KKU-100. Their migration was
measured with si-hnRNP-K treatment and in the pres-
ence or absence of PUGNAc. While siRNA of
hnRNP-K was used to suppress the expression of
hnRNP-K, PUGNAc treatment enhanced the levels of
OGPs in both cell lines (Fig. S4). Suppression of
Fig. 4. hnRNP-K mediates the expression of growth- and metastasis-related proteins in CCA cells. CCA cell lines, KKU-213 and KKU-214,
were treated with si-hnRNP-K for 24, 48, and 72 h. The expression levels of growth- and metastasis-related proteins were determined using
western blot. Expression of GAPDH was used as an internal control. The expression of (A) hnRNP-K, cyclin D1, XIAP, and cleaved caspase
3 as well as (C) EMT markers (E-cadherin, claudin-1, vimentin, and slug), and MMP2 and MMP7 was determined in si-hnRNP-K-treated cells
in comparison with those of scramble control cells. B and D are the quantitative analysis of (A) and (C) presented as mean  SD from two
independent experiments. (E) The endogenous expression of hnRNP-K and its downstream targets was compared in 2 CCA cell lines (KKU-
100 and KKU-213) with different migration/invasion abilities and O-GlcNAcylation levels. (*P < 0.05; **P < 0.01, Students’ t-test)
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hnRNP-K expression decreased the migratory activity
of MMNK1 and KKU-100 cells to 50% and 30% of
the control cells, respectively. On the other hand, ele-
vating O-GlcNAcylation by PUGNAc treatment
increased the migratory ability of both the control and
si-hnRNP-K-treated cells. Similar effects were
observed in MMNK1 and KKU-100. Together, these
results support our finding that O-GlcNAcylation and
hnRNP-K are associated with migratory ability
regardless of cell type.
3.6. O-GlcNAcylation of hnRNP-K activates the
nuclear translocation of hnRNP-K
To investigate the effect of O-GlcNAcylation on the
function of hnRNP-K, the level of O-GlcNAcylation
Fig. 5. hnRNP-K nuclear localization is regulated by O-GlcNAcylation and correlated with migratory activity of CCA cells. (A) The expression
of OGT was suppressed by siRNA for 24 h. Expression levels of OGP and hnRNP-K in siOGT- and PUGNAc-treated cells were compared
with those of control cells using western blot analysis. (B) Localization of hnRNP-K and nuclei was observed using immunocytofluorescent
staining. hnRNP-K was stained using PE (red), and cell nuclei were visualized using Hoechst 33342 (blue). Nuclear localization of hnRNP-K is
demonstrated by the purple nuclei in the merged images. The quantification of scramble siRNA- and siOGT-treated cells with nuclear
hnRNP-K is shown in the upper panel graph. The migratory ability of cells treated with scramble siRNA and siOGT is shown in the lower
panel graph. (C) The scramble siRNA- and siOGT-treated cells were allowed to migrate to the lower chamber in a Transwell culture system
for 48 h. Localization of hnRNP-K was determined in the parental and migrated cells using immunocytofluorescent staining. Cells with
nuclear hnRNP-K were counted as shown in the graphs. The images are 200 9 magnification and scale bars = 20 lm. Data are
mean  SD with **P < 0.01; ***P < 0.001 (Students’ t-test).
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was monitored using siOGT and PUGNAc. As shown
in Fig. 5A, siOGT treatment reduced cellular O-
GlcNAcylation whereas PUGNAc treatment increased
the level of O-GlcNAcylation in both KKU-213 and
KKU-214. However, neither treatments affected
hnRNP-K expression. This observation implied that
O-GlcNAcylation may not affect the expression and
stability of hnRNP-K.
As hnRNP-K is a transcription factor and the
translocation from cytoplasm to nucleus is an impor-
tant process for proper functioning of hnRNP-K, we
next explored the effect of O-GlcNAcylation on the
nuclear translocation of hnRNP-K. Cellular localiza-
tion of hnRNP-K was determined in siOGT-treated
cells using hnRNP-K immunocytofluorescence:
hnRNP-K was stained using PE (red) and cell nuclei
were visualized using Hoechst 33342 (blue). As shown
in Fig. 5B, almost all of the positive hnRNP-K signals
of scramble control cells were located in the nucleus
(red nuclei of the hnRNP-K staining; purple nuclei of
the merged images). Suppression of O-GlcNAcylation
in siOGT-treated cells retained hnRNP-K signals in
the cytoplasm (red cytoplasmic stain with blue nuclei
of the merged images). The number of cells with posi-
tive nuclear hnRNP-K was significantly reduced in
siOGT-treated cells in both KKU-213 (P < 0.001) and
KKU-214 (P < 0.01; Fig. 5B). The siOGT treatment
also significantly decreased migratory activity of both
cell lines. These data suggested that O-GlcNAcylation
modulates the nuclear localization of hnRNP-K, which
may in turn influence the migratory ability of CCA
cells.
To affirm the connection between O-GlcNAcylation
and nuclear localization of hnRNP-K, the expression
and localization of hnRNP-K in KKU-100 were
coevaluated using immunofluorescent staining. As
shown in Fig. S5A-B, the number of KKU-100 cells
with nuclear hnRNP-K was significantly lower than
that of KKU-213 and KKU-214 (P < 0.05). The dif-
ference corresponded with the level of O-GlcNAcyla-
tion and hnRNP-K expression. In addition, increased
O-GlcNAcylation by PUGNAc treatment in KKU-100
resulted in a higher proportion of cells with nuclear
hnRNP-K (Fig. S5C). These data are consistent with
those observed in KKU-213 and KKU-214 cells in
that O-GlcNAcylation conferred the nuclear transloca-
tion of hnRNP-K.
3.7. Migratory enhancement of CCA cells is
correlated with nuclear translocation of hnRNP-K
To connect the nuclear translocation of hnRNP-K
with the migratory ability of CCA cells, the localiza-
tion of hnRNP-K in the parental and migrated cells
was determined. CCA cells were transfected with
scramble siRNA or siOGT for 24 h and allowed to
migrate to the lower chamber of a Transwell system
for 48 h. Localization of hnRNP-K in the parental
cells and the migrated cells in the lower chamber
were detected using immunocytofluorescent staining.
As shown in Fig. 5C, almost all the parental and
migrated si-scramble-treated cells possessed nuclear
hnRNP-K (purple nuclei). Suppression of O-GlcNA-
cylation using siOGT, however, resulted in the reten-
tion of hnRNP-K in the cytoplasm (pink cytoplasm
with blue nuclei) and significantly reduced the num-
ber of cells with nuclear hnRNP-K (P < 0.001). Fur-
thermore, when siOGT-treated cells were allowed to
migrate to the lower compartment of the Boyden
chamber, it was found that only the fraction of cells
with nuclear hnRNP-K could migrate to the lower
chamber. These data emphasized the association of
nuclear hnRNP-K and migratory activity of CCA
cells.
3.8. Expression of nuclear hnRNP-K in CCA
tissues positively correlates with O-
GlcNAcylation levels
Upon observation of O-GlcNAc-mediated nuclear
translocation of hnRNP-K in CCA cell lines, we then
verified whether this association could be observed in
tumor tissues of CCA patients. The expression levels
of OGP and hnRNP-K with nuclear localization were
determined in 30 cases of CCA tissues using IHC,
semiquantitated according to the intensity and
Fig. 6. The expression and localization of hnRNP-K in CCA tissues correlated with OGP levels. (A) IHC staining of hnRNP-K and OGP in two
representative pairs of CCA tissues. (B) The correlations between hnRNP-K expression and OGP were analyzed by Fisher’s exact test
(N = 30). (C) Mean expression of hnRNP-K in nucleus of the high OGP group was significantly higher than those of the low OGP group
(**P < 0.01; Mann–Whitney test). (D) The positive correlation between nuclear hnRNP-K and OGP levels was shown by Spearman’s rank
correlation test. (E) Nuclear hnRNP-K in CCA patient tissues with stage I-III and IV were compared. (F) High level of nuclear hnRNP-K was
correlated with shorter CCA patients with high nuclear hnRNP-K level exhibited the shorter survival (median survival = 147 days, 95%
CI = 106–187 days), than those with low nuclear hnRNP-K level (median survival = 233 days, 95% CI = 128-338 days) (P = 0.011, Kaplan–
Meier plot and log-rank test). The IHC images are showed in 200 9 magnification with 20 lm of scale bar. (G) Schematic diagram presents
molecular mechanism by which O-GlcNAcylation regulated nuclear translocation of hnRNP-K in association with progression of CCA.
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frequency of the positive signal with IHC scores.
hnRNP-K and OGP were generally observed in both
the nucleus and cytoplasm of CCA tissues but
nuclear staining with different intensities was predom-
inantly observed (Fig. 6A). Expression of nuclear
hnRNP-K and OGP was categorized according to the
median of IHC scores as low or high levels, and the
correlation of these two factors was analyzed. Posi-
tive correlations between number of CCA cells with
nuclear hnRNP-K and those with OGP expression
were observed (Fig. 6B, Fisher’s exact test). CCA tis-
sues with high nuclear hnRNP-K expression also had
high OGP expression. In addition, higher expression
of nuclear hnRNP-K was observed in CCA tissues
with high OGP expression than those with low OGP
expression (Fig. 6C, Mann–Whitney test). Correla-
tions between the expression levels of nuclear OGP
and those of nuclear hnRNP-K are shown by Spear-
man rank correlation with r = 0.529 (Fig. 6D).
3.9. High expression of tissue nuclear hnRNP-K is
associated with metastatic stage and poor
clinical outcome of CCA patients
To implicate the clinical significance of hnRNP-K in
CCA, expression of tissue hnRNP-K and clinicopatho-
logical features of CCA patients were determined in 38
CCA subjects. Nuclear hnRNP-K expression was cate-
gorized as low or high based on median IHC score,
and univariate analysis was performed. CCA tissues
with metastatic stage (stage IV) exhibited higher levels
of nuclear hnRNP-K than those with nonmetastatic
stages (stages I–III) (Table 2, Fig. 6E). The Kaplan–
Meier analysis indicated that patients whose tumor
possessed high nuclear hnRNP-K had significantly
shorter survival than those possessed low nuclear
hnRNP-K (Fig. 6F, P = 0.011, log-rank analysis).
Univariate Cox proportional hazard-regression analy-
sis was next performed to determine the influence of
nuclear hnRNP-K levels and clinicopathological char-
acteristics on overall survival of CCA patients. As
shown in Table 3, high level of nuclear hnRNP-K was
significantly correlated with overall survival
(P = 0.014) and an independent prognostic factor of
CCA (HR = 2.540, 95% CI = 1.213–5.317, P = 0.013).
4. Discussion
Several O-GlcNAcylated proteins (OGPs) have been
reported for their roles in cancer proliferation, metas-
tasis, metabolism, angiogenesis, stress response,
replicative immortality, and resistance to apoptosis
(Ma and Vosseller, 2013). Although it is likely that
there are more cancer-related OGPs involved in these
processes, many remain unidentified. In this study, we
used Click-iTTM O-GlcNAc Enzymatic Labeling System
and mass spectrometry to reveal OGPs that are related
to the progression of CCA. Among these, hnRNP-K
was shown to be O-GlcNAcylated and associated with
Table 2. The correlation between nuclear hnRNP-K levels and
clinicopathological data of CCA patients.
Variables (N)
Nuclear hnRNP-K
P-valueLow High
Age (38)
≤ 56 (21) 13 8 0.847
> 56 (17) 10 7
Sex (38)
Male (25) 16 9 0.544
Female (13) 7 6
Histological type (38)
Papillary (11) 7 4 0.802
Nonpapillary (27) 16 11
CCA stage (30)
I–III (13) 12 1 0.001*
IV (17) 5 12
*P < 0.001, Fisher’s exact test (two-sided).
Table 3. Univariate and multivariate analysis of factors influencing
overall survival in CCA patients
Variables
(N)
Univariate analysis Multivariate analysis
HR
95%
CI
P-
value HR
95%
CI
P-
value
Age (38)
≤ 56 (21) 1
> 56 (17) 0.741 0.384-
1.428
0.370
Sex (38)
Male (25) 1
Female (13) 1.302 0.650-
2.609
0.456
Histological type (38)
Papillary (11) 1 1
Nonpapillary
(27)
1.353 0.676-
2.706
0.393 1.439 0.702-
2.949
0.320
CCA stage (30)
I–III (13) 1
IV (17) 1.850 0.835-
4.102
0.130
Nuclear hnRNP-K (38)
Low (23) 1 1
High (15) 2.528 1.208-
5.294
0.014* 2.540 1.213-
5.317
0.013*
CI, confidence interval; HR, hazard ratio.
*P < 0.05, Cox proportional hazard-regression test.
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malignant progression phenotypes of CCA cells. In
addition, this study is the first demonstration that O-
GlcNAc modification has an impact on nuclear
translocation of hnRNP-K and mediates the migratory
ability of CCA cells. The association of O-GlcNAcyla-
tion and the nuclear translocation of hnRNP-K with
metastasis and poor patient outcome were also demon-
strated.
The contribution of O-GlcNAcylation in the pro-
gression of CCA has been sequentially reported (Phoo-
mak et al., 2012, 2016, 2017). Immunohistochemistry
of OGP, OGT, and OGA in tumor tissues from
patients revealed that CCA tissues had increased
expression of OGPs which resulted from the increase
of OGT and decrease of OGA expression. Correlation
of high OGPs in CCA tissues with poor clinical out-
comes of CCA patients was observed (Phoomak et al.,
2012). Recently, O-GlcNAcylation was shown to
enhance progressive phenotypes of CCA cells by
increasing high mannose N-linked glycans at the cell
surface through regulation of FOXO3 and MAN1A1
expression (Phoomak et al., 2018). The connection of
O-GlcNAcylation to the migration and invasion abili-
ties of CCA cells was shown to be partly via activation
of nuclear translocation of NF-jB (Phoomak et al.,
2016). Reducing the cellular O-GlcNAcylation by
siOGT, however, suppressed migration and invasion
abilities of CCA cells to a lower extent than the inacti-
vation of NF-jB (Phoomak et al., 2016). This implies
that there might be other O-GlcNAcylated proteins
together with NF-jB that modulate progression of
CCA cells. In the present study, novel OGPs that asso-
ciated with progressive phenotypes of CCA were
explored.
O-GlcNAc is particularly difficult to detect due to
biological and technical challenges. First, cells contain
high levels of hydrolase enzymes which can rapidly
remove O-GlcNAc when cells are damaged or lysed,
resulting in loss of O-GlcNAc during protein isolation
(Greis and Hart, 1998; Hart et al., 2007). Second, O-
GlcNAc appears on a protein at substoichiometric
amounts and easily falls off when it is ionized in a
mass spectrometer (Greis and Hart, 1998). Third, the
signal of O-GlcNAcylated peptides, if remained, is
almost always suppressed by the higher abundance of
unmodified peptides (Greis and Hart, 1998). To deter-
mine the OGPs that modulate progression of CCA
cells, we first increased the signal of OGPs by inhibit-
ing the activity of OGA (an enzyme that removes
GlcNAc from the proteins) with PUGNAc. The treat-
ment did increase OGP levels in both CCA cell lines
(Fig. 1A) and enhanced the progressive phenotypes of
CCA cells. These results support the association of
O-GlcNAcylation and progression of CCA cells. The
sensitivity to detect O-GlcNAcylated peptides was ele-
vated using Click-iTTM O-GlcNAc Enzymatic Labeling
System, which stabilized the GlcNAc moieties on the
peptide by GalNAz labeling. The system allowed us to
select and detect only O-GlcNAcylated peptides for
mass spectrometric analysis. In this study, there were
over 100 OGPs detected, of which 21 were commonly
found in both CCA cell lines, KKU-213 and KKU-
214 (Table 1).
The OGPs found in this study were checked against
a curated database of experimentally verified O-
GlcNAcylated proteins using the Database of O-
GlcNAcylated Proteins and Sites (dbOGAP) (Wang
et al., 2011). Twelve proteins were identified as novel
OGPs. Among these, hnRNP-K, a member of the
RNA/DNA-binding protein family, was selected for
further verification (Lu and Gao, 2016). hnRNP-K has
a unique RNA- and DNA-binding component of
ribonucleoproteins, which is involved in several cellular
processes, including chromatin remodeling, transcrip-
tion, mRNA processing, translation, nuclear transport,
signal transduction, and DNA repair (Gao et al.,
2013; Lu and Gao, 2016). It can be further modified
by several post-translational modifications, including
phosphorylation, that regulates its function and inter-
actions with different binding partners (Barboro et al.,
2014a). There are several studies that have indicated
the significant roles of hnRNP-K in the development
and progression of several cancers, including cancers
of the bladder (Chen et al., 2017), breast (Dhanjal
et al., 2014), colon (Zhang et al., 2016b), pancreas
(Zhou et al., 2010), prostate (Barboro et al., 2014b),
lung (Li et al., 2011), cervix (Zhang et al., 2016a), and
liver (Xiao et al., 2013).
In the present study, we demonstrated that hnRNP-
K expression is related to cell proliferation, migration,
and invasion which are hallmarks of cancer progres-
sion. Silencing of hnRNP-K expression with specific
siRNA significantly decreased cell growth, migration,
and invasion of both CCA cell lines tested. Suppres-
sion of hnRNP-K expression decreased the key effec-
tors of cell growth (cyclin D1 and XIAP) and
increased the level of cleaved caspase 3, a marker of
apoptosis (Fig. 4A,B). The impact of hnRNP-K on
cell proliferation was firstly shown in colon (Sugimasa
et al., 2015), liver, and bladder cancers (Chen et al.,
2017; Xiao et al., 2013). In the current study, hnRNP-
K was shown to be involved in cell migration and
invasion of CCA cells. Reduced hnRNP-K expression
significantly diminished the migration and invasion
abilities of CCA cells and decreased the expression of
the effector markers of migration and invasion—EMT
352 Molecular Oncology 13 (2019) 338–357 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
O-GlcNAcylation of hnRNP-K induces CCA metastasis C. Phoomak et al.
markers (cadherin, claudin-1, vimentin, slug) and
metastasis-related proteins (MMP2, MMP7). The
association of these markers and progressive pheno-
types has been reported in several cancer cells (Chung
et al., 2014; Gao et al., 2013; Zhang et al., 2016b;
Zhou et al., 2010). Cyclin D1 and MMP2 have been
demonstrated to be the direct downstream targets of
hnRNP-K. Decreased expression of cyclin D1 was
shown in hnRNP-K suppressing bladder cancer cells
(Chen et al., 2017). In addition, increased transcrip-
tion activity and mRNA level of MMP2 were shown
in hnRNP-K enhancing colorectal cancer cell lines
(Zhu et al., 2017). Whether the EMT markers (cad-
herin, claudin-1, vimentin, slug) and MMP7 are direct
downstream targets of hnRNP-K remain to be
explored.
The connection of O-GlcNAcylation, hnRNP-K,
and progression of CCA cells was further supported
by the study of KKU-100 which exhibited lower
migration and invasion activities than KKU-213. The
levels of O-GlcNAcylation and hnRNP-K expression
as well as the downstream signals of cell proliferation
and EMT markers related to hnRNP-K were also
lower in KKU-100 than those in KKU-213. The asso-
ciation of hnRNP-K and O-GlcNAcylation with cell
migration is irrespective of cell type, as monitoring of
hnRNP-K expression or O-GlcNAcylation levels was
also able to affect the migratory ability of the immor-
tal cholangiocyte, MMNK1 and a less aggressive
CCA cell line, KKU-100 (Fig. S4). These collective
results establish a correlation between the expression
of hnRNP-K and O-GlcNAcylation with the migra-
tory ability of CCA cells.
For this study, hnRNP-K was justified as a novel
OGP based on the analysis using Database of O-
GlcNAcylated Proteins and Sites (dbOGAP) (Wang
et al., 2011). However, more recently, O-GlcNAcyla-
tion of hnRNP-K has been identified and reported
previously in breast cancer (Champattanachai et al.,
2013; Drougat et al., 2012). The modulation of O-
GlcNAc on hnRNP-K was confirmed by anti-OGP
and anti-hnRNP-K immunoprecipitation as well as
sWGA pull-down assays (Fig. 2). In agreement with
this phenomenon, the elevation of O-GlcNAcylation
by PUGNAc treatment also increased the level of
O-GlcNAcylated hnRNP-K in CCA cells. This evi-
dence provides a link between global O-GlcNAcylation
and O-GlcNAcylated hnRNP-K.
Even though the modification of hnRNP-K by
O-GlcNAcylation has been shown, the effect of
O-GlcNAcylation on the regulation of hnRNP-K
expression and action is unknown. The present study
reported for the first time the effect of GlcNAc
modification on the nuclear translocation of hnRNP-
K. The O-GlcNAcylation of CCA cells was modulated
using siOGT or PUGNAc treatment. Treated cells
with siOGT significantly decreased O-GlcNAcylation
levels whereas PUGNAc treatment reversed the obser-
vation (Fig. 5A). Modulating levels of O-GlcNAcyla-
tion have no effect on the expression of hnRNP-K but
did affect the O-GlcNAcylated level of hnRNP-K
(Fig. 2). As hnRNP-K action is in the nucleus, we
then investigated the effect of O-GlcNAcylation on
nuclear translocation of hnRNP-K. To visualize
nuclear hnRNP-K in relation with O-GlcNAcylation,
the immunocytofluorescence of hnRNP-K was
assessed in CCA cells treated with scramble siRNA or
siOGT. As demonstrated in Fig. 5B, suppression of
O-GlcNAcylation by siOGT in KKU-213 and KKU-
214 cells significantly reduced the number of cells with
positive nuclear hnRNP-K. Conversely, increased O-
GlcNAcylation in KKU-100 by PUGNAc treatment
increased the number of cells with nuclear hnRNP-K
(Fig. S5C). O-GlcNAc-induced nuclear translocation
of other proteins besides hnRNP-K has also been
observed, for example, NF-kB in CCA (Phoomak
et al., 2016) and lung cancer (Yang et al., 2008);
hnRNP-A1 (Roth and Khalaila, 2017) and b-catenin
in colorectal cancer (Olivier-Van Stichelen et al.,
2012).
The significance of nuclear localization of hnRNP-K
was linked to migration of CCA cells by the observa-
tion that almost all migrated cells of siOGT-treated
cells had nuclear hnRNP-K. The positive associations
of O-GlcNAcylation and nuclear hnRNP-K as well as
progressive phenotypes were also evident in tumor tis-
sues from CCA patients (Fig. 6A–D). High level of
nuclear hnRNP-K in CCA tissues was associated with
metastatic stage and shorter survival of CCA patients.
The association of hnRNP-K with poor prognosis has
also been reported in colon cancer (Carpenter et al.,
2006).
Collectively, the results above demonstrated the
function of O-GlcNAcylation on nuclear translocation
of hnRNP-K. Whether this association is the direct
effect of O-GlcNAcylation on hnRNP-K, however, is
still obscure. It has been shown that nuclear transloca-
tion of hnRNP-K is mediated via activation of Akt
(Barboro et al., 2014b; Li et al., 2011), which is also
regulated by O-GlcNAcylation (Phoomak et al., 2016).
In CCA cells, the association of nuclear translocation
of hnRNP-K and O-GlcNAcylation is possibly the
direct effect of O-GlcNAcylation on hnRNP-K or
formed indirectly via Akt activation. Further experi-
ments using site-directed mutagenesis of O-GlcNAcyla-
tion on hnRNP-K are required for the complete
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understanding of the precise role of O-GlcNAcylation
on nuclear translocation of hnRNP-K.
Our results also underscore the impact of nuclear
translocation of hnRNP-K on the migratory ability of
CCA cells. First, siOGT treatment inhibited nuclear
translocation of hnRNP-K and concurrently decreased
migration of CCA cells. Second, almost all migrated
cells detected in migration assay had positive nuclear
hnRNP-K. These findings prompt further development
of inhibitors of hnRNP-K nuclear translocation to
diminish CCA progression.
5. Conclusion
Primarily in the nucleus and cytoplasm, 12 novel
OGPs associated with progression of cancer were
revealed in CCA cells. Of these, hnRNP-K was vali-
dated for its O-GlcNAc modification and its molecular
mechanism in promoting progression of CCA
(Fig. 6E). The impact of hnRNP-K on progressive
phenotypes—cell growth, migration, and invasion—
was emphasized. O-GlcNAcylation was proved to be
necessary for nuclear translocation of hnRNP-K that
subsequently activates several downstream targets of
hnRNP-K (cyclin D1, XIAP, caspase 3, EMT mark-
ers, and MMP2 and MMP7). Expression of nuclear
hnRNP-K in tumor tissues predicted the metastatic
stage and associated with poor patient outcome. Inhi-
bition of nuclear translocation of hnRNP-K may be a
new strategy for CCA treatment.
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